Progesterone Receptor Negative Recruiting Phase 1 Trials for Durvalumab (DB11714)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs